Panelists discuss how the Inflation Reduction Act (IRA) might influence health care systems’ selection and utilization of Bruton tyrosine kinase (BTK) inhibitors, particularly through changes in ...

Glenmark shares on Monday ended 0.68% up at ₹1,600.85 apiece on BSE. New Delhi: Glenmark Pharmaceuticals on Monday said it ...

The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper ...

Glenmark Pharmaceuticals on Monday said it will launch cancer treatment drug zanubrutinib in India following approval by the ...

Participants receiving combination therapy had a 42% reduction in the risk of disease progression or death vs those receiving acalabrutinib monotherapy.

Glenmark Pharmaceuticals to launch Brukinsa (zanubrutinib) in India after DCGI approval, offering treatment for five B-cell ...

Glenmark Pharmaceuticals launches zanubrutinib (Brukinsa), a BTK inhibitor for treating five B-cell malignancies in India, ...

This trial demonstrated that 77% of subjects treated with Calquence and venetoclax combo and 83% of those who received the ...

Glenmark Pharmaceuticals is set to launch zanubrutinib in India, following its approval from the Drugs Controller General of ...

Glenmark Pharmaceuticals rose 1% to Rs 1605.80 after the drug maker announced the upcoming launch of zanubrutinib in India, following approval from the Drugs Controller General of India (DCGI).

Glenmark Pharmaceuticals has announced the upcoming launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI).